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Volume 60, Number 4 Abstracts 1109a 1-hour digestion. At 20 minutes, the digestion solution with sonicat-
ion reduced plaque area by 46% (P < .05) compared with 2% without
sonication, which was insigniﬁcant.
Conclusions: Our therapy can safely and effectively reduce athero-
sclerotic plaque burden ex vivo without damaging the arterial wall. Optimi-
zation of this therapy will allow for shorter, more clinically relevant digestion
times. Ultimately, this therapy shows promise as a novel atraumatic method
to reduce atherosclerotic lesions in situ.
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Objectives: Over the past decade, the use of endovascular grafts for
endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms has
increased signiﬁcantly. With the increased use of endovascular techniques,
there has been a higher volume of endovascular complications. In some in-
stances, it is not feasible or necessary to excise the entire endovascular graft,
suggesting that partial excision may be indicated. However, there is not
enough literature to support the efﬁcacy of partial graft excision after
EVAR. This study was designed to evaluate our institution’s outcomes of
partial explant patients who underwent EVAR.
Methods: A retrospective analysis of partially explanted EVARs
requiring late explantation (>1 month) from 1999 to 2012 was per-
formed using a database. Each patient’s postoperative computed tomog-
raphy (CT) scan was compared with the most recent follow-up CT and
subsequently evaluated using computer software to measure graft location
within the aorta to determine if any graft migration occurred. Indication
for graft removal, type of excision, length of follow-up, and mortality
were reviewed.
Results: Between 1999 and 2012, 22 patients had a partial late
EVAR explantation. Of these 22 patients, there were four patients
with proximal components remaining, 17 patients with distal compo-
nents remaining, and one patient with both proximal and distal com-
ponents left. Nine of the 22 (41%) had postoperative and follow-up
CT imaging, of which none of these patients had migration of their
remaining graft components. The average length of follow-up in these
nine patients was 25.9 months. Nine of the 22 patients (41%) were
lost to follow-up before having two postoperative CT scans. Four of
the 22 patients (18%) died secondary to postoperative infection, shock,
and organ failure before being discharged from the hospital after par-
tial EVAR explantation.
Conclusions: Partial EVAR explantation is an option in instances
where total excision of an endovascular aortic graft would not be tolerated.
All of our partial late EVAR explantation patients who had postexplant CT
imaging and follow-up CT imaging demonstrated no migration of their
endovascular grafts. Further follow-up in patients with partial late EVAR
explantation is necessary to determine if partial graft excision after EVAR
is a durable treatment option in the future.
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Objectives: This study evaluated the safety and effectiveness of ultra-
sound accelerated thrombolysis in acute pulmonary embolism (PE).
Methods: A retrospective study of 45 patients (25 male, 20 fe-
male) was performed to evaluate treatment of acute PE at a single
center from January 2011 to December 2013. All patients were diag-
nosed with computed tomography (CT) or VQ scan and had hemody-
namic instability or right heart strain evidenced by right ventricular
dilatation, septal deviation, or hypokinesis by echocardiography or
CT. EkoSonic catheters (EKOS Corporation, Bothell, Wash) were
placed into the affected pulmonary arteries. Thirteen patients received
an average bolus of 30 mg tissue plasminogen activator with an
average infusion dose of 21.3 mg (range, 15-48 mg) over 14 hours
(range, 8-21 hours).Results: Hypotension (systolic blood pressure <100 mmHg) was
present in 13 patients, with 100% resolution by treatment completion.
Tachycardia (heart rate >100 beats/min) was present in 26 patients
and resolved in 92% by treatment completion. The average heart rate
for all patients decreased from 109 to 77 beats/min over the treatment
period. Direct pulmonary artery pressure measurement showed an
average decrease of 21.5 mm Hg. Postprocedure echocardiography
demonstrated complete resolution of cardiac dysfunction in 64%. There
were no deaths through 90 days of follow-up and no major periproce-
dural bleeding events.
Conclusions: The current study demonstrates the safety and effec-
tiveness of using ultrasound accelerated thrombolysis to treat acute pulmo-
nary embolism.
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Objectives: CREST documented similar outcomes for carotid artery
stenting (CAS) and carotid endarterectomy (CEA). This study evaluated
contemporary outcomes for patients undergoing carotid intervention in
Michigan.
Methods: We evaluated the outcomes for consecutive carotid inter-
ventions at 22 hospitals in Michigan between January 1, 2012, and
December 31, 2013, using data derived from a prospective, statewide qual-
ity improvement registry. Outcomes of interest included the occurrence of
any transient ischemic attack/stroke, ipsilateral stroke, myocardial infarction
(MI), death, and composite end points of stroke/death and stroke/MI/
death. Data were stratiﬁed on the basis of preoperative symptom status.
The Cochran-Mantel-Haenszel test was used to determine the common
odds ratio from stratiﬁed binary variables, and propensity score matching
(PSM) was used to account for demographic differences between CAS
and CEA patients.
Results: Of 3136 patients undergoing carotid intervention, CEA
was performed in 2482 patients (79.1%) and CAS in 654 (20.9%). For
patients undergoing CEA, the rates of in-hospital transient ischemic
attack (TIA)/stroke, stroke/death, and stroke/MI/death were 1.9% (n
¼ 47), 2.3% (n ¼ 57), and 2.7% (n ¼ 68). For patients undergoing
CAS, the rates of in-hospital TIA/stroke, stroke/death, and stroke/
MI/death were 5.5% (n ¼ 36), 6.3% (n ¼ 41), and 6.7% (n ¼ 44).
When stratiﬁed on the basis of preoperative symptom status, the rate
of TIA/stroke was signiﬁcantly higher for CAS than for CEA in both
asymptomatic (5.1% vs 1.5%; odds ratio [OR], 3.6; 95% conﬁdence inter-
val [CI], 1.9-6.7) and symptomatic (6.0% vs 2.7%; OR, 2.3; 95% CI,
1.2-4.3) patients (common OR, 2.8; 95% CI, 1.8-4.4; P < .001).
Follow-up data were available at 30 days for 2838 (90.4%) and at 1
year for 1131 (36.1%). The rates of subsequent stroke, MI, and death
were not different between CAS and CEA at 30 days or 1 year. In pro-
pensity matched analysis (n ¼ 1308), no differences in the rate of stroke,
MI, or death were observed.
Conclusions: In Michigan, CAS is associated with increased rates
of in-hospital TIA/stroke as well as the composite end points of
stroke/death and stroke/MI/death. The complication rate was espe-
cially high among patients with asymptomatic disease. Patient-speciﬁc
and clinical decision-making factors appear to explain the observed dif-
ferences in outcomes, emphasizing the importance of patient selection
in CAS.
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Objectives: Renal artery stenting has not proven to be efﬁcacious for
the treatment of renovascular hypertension (ASTRAL, CORAL). This study
provides evidence using Doppler ﬁndings and ﬂuid mechanics that the
